glp-1 and sibo medications can be powerful tools for blood sugar weight loss but they also slow gut motility more than most people realize. GLP-1 naturally delays stomach emptying and intestinal movement. When ACG 2025 Annual Meeting Posters

PMID: 9849822 Reported Bone-growth effects (preclinical) Longitudinal bone-growth rate increase without IGF-1 elevation (15-day rat study) Johansen and colleagues (Growth Horm IGF Res 1999) reported that adult female rats dosed with ipamorelin for 15 days showed a dose-dependent increase in longitudinal bone-growth rate (from 42 m/day in controls to 4452 m/day) with concurrent body-weight gain

The result is faster fat loss (about 10% more than Ozempic), and because you have more mechanisms of action for fat loss, you don't need to hammer the GLP-1 as hard, hence less nausea but still really potent at blunting hunger signaling

In patients in whom the major therapeutic goal is the compelling need to minimize the therapeutic risk pf hypoglycaemia, DPP-4 inhibitors are recommended as second line therapy after metformin failure at the same level as second line treatment options with GLP-1 receptor agonists, SGLT-2 inhibitors, or TZDs

Sep 14 2016;6:33052

ChenSHendersonAPetrielloMCRomanoKAGearingMMiaoJet al

But every step led me closer to my purpose: to help others feel beautiful, empowered, and aligned.